- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Atezolizumab – November 2019
Atezolizumab: Solution concentrate for I.V. infusion 840 mg in 14 mL; Tecentriq®
Last updated
30 May 2025